drugset

drugset / Trial / NCT00757757

A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

NCT00757757 ↗

Phase 1/2 Terminated 3 enrolled Novartis Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases

Timeline

Start: 2008-09
Primary completion: 2009-08
Completion: 2009-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MCS110	Monoclonal antibody	—	—

Indications